Absorbed doses to patients from 191Pt-, 193mPt- and 195mPt-cisplatin

Applied Radiation and Isotopes

Volumn 51, Issue 5, 1999, Pages 581-586

  Areberg, Johan ^a   Norrgren, Kristina ^a   Mattsson, S Ören ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABSORPTION; CHEMOTHERAPY; DIAGNOSTIC RADIOGRAPHY; DOSIMETRY; PHARMACOKINETICS; PLATINUM; RADIOISOTOPES; SYNTHESIS (CHEMICAL); TISSUE;

CHEMOTHERAPEUTIC AGENTS;

RADIOTHERAPY;

CISPLATIN; ISOTOPE; PLATINUM; PLATINUM 191; PLATINUM 193M; PLATINUM 195M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CARCASS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG SCREENING; DRUG SYNTHESIS; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; IMAGING; INTESTINE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY; LIVER; MUSCLE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOASSAY; SKIN;

ABSORPTION; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; LIVER; MODELS, BIOLOGICAL; PLATINUM; RADIATION DOSAGE; RADIOISOTOPES; RADIOMETRY; TISSUE DISTRIBUTION;

EID: 0032798840     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(99)00082-2     Document Type: Article

References (34)

1. 191Pt-cisplatin. Acta Oncol. 38:1999;221-228.
2. Bardiès M., Myers M.J. Computational methods in radionuclide dosimetry. Phys. Med. Biol. 41:1996;1941-1955.
3. Bonetti A., Franceschi T., Apostoli P., Cetto G.L., Recaldin E., Molino A., Leone R. Cisplatin pharmacokinetics in elderly patients. Ther. Drug Monit. 16:1994;477-482.
4. Bonetti A., Franceschi T., Apostoli P., Messori A., Sperotto L., Cetto G.L., Molino A., Leone R. Cisplatin pharmacokinetics using a five day schedule during repeated courses of chemotherapy in germ cell tumors. Ther. Drug Monit. 17:1995;25-32.
5. Chen C.-T., Harper P.V., Lathrop K.A. A simple dynamic model for calculating radiation absorbed dose to the bladder wall. Proceedings of Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN, USA. 1985;587-612 National Technical Information Service, Springfield, VA.
6. Eastman A., Schulte N., Sheibani N., Sorensson C.M. Mechanisms of resistance to platinum drugs. Nicolini M., Platinum and other metal coordination compounds in cancer chemotherapy. 1988;248-254 Martinus Nijhoff, Boston.
7. Farris F.F., Dedrick R.L., King F.G. Cisplatin pharmacokinetics: applications of a physiological model. Toxicol. Lett. 43:1988;117-137.
8. 13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med. 28:1987;1844-1852.
9. Gorodetsky R., Mou X., Vexler A., Kaufman B., Catane R., Loewenthal E. Noninvasive follow-up of platinum pharmacokinetics in the skin of patients on cisplatin chemotherapy. Cancer. 72:1993;446-454.
10. 13N]cisplatin. J. Label. Comp. Radiopharm. 22:1985;509-516.
11. Holding J.D., Lindup W.E., Bowdler D.A., Siodlak M.Z., Stell P.M. Disposition and tumor concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck. Br. J. Clin. Pharmac. 32:1991;173-179.
12. Howell R.W., Sastry K.S.R. Cis-platinum-193m: Its microdosimetry and potential for chemo-Auger combination therapy of cancer. Schlafke-Stelson A.T., Watson E.E., Proceedings of Fourth International Radiopharmaceutical Dosimetry Symposium. 1986;493-513 National Technical Information Service, Springfield, VA.
13. Howell R.W. Radiation spectra for Auger-electron emitting radionuclides: Report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med. Phys. 19:1992;1371-1383.
14. Howell R.W., Narra V.R., Sastry K.S.R., Rao D.V. On the equivalent dose for Auger electron emitters. Radiat. Res. 134:1993;71-78.
15. Humm J.L., Howell R.W., Rao D.V. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med. Phys. 21:1994;1901-1915.
16. ICRP . Limits for intakes of radionuclides by workers. Part I. ICRP Publication. vol. 30:1979;Pergamon Press, Oxford.
17. ICRP . 1990 recommendations of the International Commission on Radiological Protection. ICRP Publication. vol. 60:1991;Pergamon Press, Oxford.
18. Kinsey, R.R. et al., 1997. The NUDAT/PCNUDAT program for nuclear data, paper submitted to the 9th International Symposium of Capture Gamma-Ray Spectroscopy and Related Topics, Budapest, Hungary, October 1996. Data extracted from the PCNUDAT, release version 2.6 (March 27, 1997).
19. Kusumoto T., Maehara Y., Sakaguchi Y., Kakeji Y., Nohzuka T., Furusawa M., Sugimachi K. Tissue distribution of cis-diamminedichloroplatinum(II) following intraperitoneal administration to patients with recurrent gastric cancer. Oncology. 50:1993;214-217.
20. 195mPt. J. Nucl. Med. 14:1973;191-195.
21. Moretti J.L., Caglar M., Duran-Cordobes M., Morere J.F. Can nuclear medicine predict response to chemotherapy. Eur. J. Nucl. Med. 22:1995;97-100.
22. Muggia F.M. Testicular cancer and the legacy of chemotherapy. Cancer Chemother. Pharmacol. 15:1985;1-5.
23. Owens S.E., Thatcher H., Sharma H., Adam N., Harrisson R., Smith A., Zaki A., Baer J.C., McAuliffe C.A., Crowther D., Fox B.W. In vivo distribution studies of radioactively labeled platinum complexes; cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV), cis-dichloro-bis-cyclopropylamine platinum (II) and cis-diammine 1,1-cyclobutanedicarboxylate platinum (II) in patients with malignant disease, using a gamma camera. Cancer Chemother. Pharmacol. 14:1985;253-257.
24. Rosenberg B., Van Camp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumor agents. Nature. 222:1969;385-386.
25. 195mPt-cis-dichlorodiammine platinum (II) in man. J. Nucl. Med. 15:1974;349-351.
26. Snyder W.S., Ford M.R., Warner G.G., Watson S.B. 'S', absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlets No 11. 1975;Oak Ridge National Laboratory, Oak Ridge, TN.
27. Snyder W.S., Ford M.R., Warner G.G. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlets No. 5. 1978;Oak Ridge National Laboratory, Oak Ridge, TN. (revised).
28. Stewart D.J., Benjamin R.S., Luna M., Feun L., Caprioli R., Seifert W., Loo T.L. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother. Pharmacol. 10:1982;51-54.
29. Stewart D.J., Leavens M., Maor M., Feun L., Luna M., Bonura J., Caprioli R., Loo L.T., Benjamin R.S. Human central nervous system distribution of cis-Diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 42:1982;2474-2479.
30. Takahashi K., Seki T., Nishikawa K., Minamide S., Iwabuchi M., Ono M., Nagamine S., Horinishi H. Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin. Jpn. J. Cancer Res. 76:1985;68-74.
31. Thatcher N., Sharma H., Harrison R., Smith A., Zaki A., McAuliffe C.A., Crowther D., Fox B.W. Blood clearance of three radioactively labeled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. Cancer Chemother. Pharmcol. 9:1982;13-16.
32. Tothill P., Klys H.S., Matheson L.M., McKay K., Smyth J.F. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur. J. Cancer. 28A:1992;1358-1361.
33. Uozumi J., Ueda T., Yasumasu T., Koikawa Y., Naito S., Kumazawa J., Sueishi K. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans. Int. Urol. Nephrol. 25:(3):1993;215-220.
34. Vermorken J.B., van der Vijgh W.J.F., Klein I., Gall H.E., van Groeningen C.J., Hart G.A.M., Pinedo H.M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusion of cisplatin. Clin. Pharmacol. Ther. 39:1986;136-144.